InvestorsObserver
×
News Home

Analyst Rating: Will AcelRx Pharmaceuticals Inc (ACRX) Stock Outperform the Market?

Friday, September 03, 2021 11:25 AM | InvestorsObserver Analysts

Mentioned in this article

Analyst Rating: Will AcelRx Pharmaceuticals Inc (ACRX) Stock Outperform the Market?

Analysts who follow AcelRx Pharmaceuticals Inc (ACRX) on average expect it to increase 460.75% over the next twelve months. Those same analysts give the stock an average rating of Strong Buy. That average rating earns ACRX an Analyst Ranking of 75, which means it ranks higher than 75 of stocks, based on data compiled by InvestorsObserver.

Overall Score - 5
Wall Street analysts are rating ACRX a Strong Buy today. Find out what this means to you and get the rest of the rankings on ACRX!

Why are Analyst Ratings Important?

Fundamental research of the underlying health of a company can be an extremely useful resource when making investment decisions. Analysts observe growth prospects and forecasted earnings of companies to gain a comprehensive view of particular industries. This data allows traders to react before numbers are officially reported. InvestorsObserver takes the ratings from these analysts and percentile ranks those aveages. This allows you to compare stocks extensively and in more detail than the common buy/hold/sell ratings.

What's Happening With AcelRx Pharmaceuticals Inc Stock Today?

AcelRx Pharmaceuticals Inc (ACRX) stock is trading at $1.07 as of 11:23 AM on Friday, Sep 3, a decline of -$0.02, or -2.29% from the previous closing price of $1.09. The stock has traded between $1.06 and $1.10 so far today. Volume today is less active than usual. So far 177,602 shares have traded compared to average volume of 1,308,897 shares. Click Here to get the full Stock Report for AcelRx Pharmaceuticals Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App